Skip to main content

Carafate Disease Interactions

There are 2 disease interactions with Carafate (sucralfate).

Major

Sucralfate (applies to Carafate) hypophosphatemia

Major Potential Hazard, High plausibility. Applicable conditions: Phosphate Imbalance

Sucralfate has phosphate binding properties for which the drug is sometimes used therapeutically. However, hypophosphatemia may occur in some patients, regardless of renal status. Therapy with sucralfate should be administered cautiously in patients with preexisting hypophosphatemia. Monitoring phosphate levels in these patients is recommended.

References

  1. McCarthy DM (1991) "Sucralfate." N Engl J Med, 325, p. 1017-25
  2. Chines A, Pacifici R (1990) "Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature." Calcif Tissue Int, 47, p. 291-5
  3. (2001) "Product Information. Carafate (sucralfate)." Hoechst Marion Roussel
Major

Sucralfate (applies to Carafate) renal dysfunction

Major Potential Hazard, Moderate plausibility.

Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum. Additionally, aluminum does not cross dialysis membranes as it is bound to albumin and transferrin plasma proteins. Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy), have been described in patients with renal impairment. Sucralfate must be used with caution in patients with chronic renal failure.

References

  1. McCarthy DM (1991) "Sucralfate." N Engl J Med, 325, p. 1017-25
  2. Robertson JA, Salusky IB, Goodman WG, Norris KC, Coburn JW (1989) "Sucralfate, intestinal aluminum absorption, and aluminum toxicity in a patient on dialysis." Ann Intern Med, 111, p. 179-81
  3. Withers DJ, Woolf AS, Kingswood JC, Tsang WN, Mansell MA (1989) "Encephalopathy in patient taking aluminium-containing agents, including sucralfate ." Lancet, 2, p. 674
  4. Min DI, D'Elia JA (1992) "Sucralfate-associated aluminum toxicity in a patient with renal failure: treatment with deferoxamine." Clin Pharm, 11, p. 636-9
  5. Pai S, Melethil S, Cuddy P, Hall T (1987) "Elevation of serum aluminum in humans on a two-day sucralfate regimen." J Clin Pharmacol, 27, p. 213-5
  6. Campistol JM, Cases A, Botey A, Revert A (1989) "Acute aluminum encephalopathy in an uremic patient." Nephron, 51, p. 103-6
  7. (2001) "Product Information. Carafate (sucralfate)." Hoechst Marion Roussel
View all 7 references

Carafate drug interactions

There are 157 drug interactions with Carafate (sucralfate).

Carafate alcohol/food interactions

There is 1 alcohol/food interaction with Carafate (sucralfate).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer